Adipose Insulin Resistance in Obese Adolescents Across the Spectrum of Glucose Tolerance
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
CONTEXT: Adipocytes represent an important insulin-responsive tissue taking an active part in glucose metabolism. OBJECTIVE: This study sought to assess adipose tissue insulin resistance (IR) across the spectrum of glucose tolerance and to test its relation with free fatty acid (FFA) suppression during an oral glucose tolerance test (OGTT). DESIGN AND SETTING: A cross-sectional analysis of a pediatric clinic-derived cohort of obese adolescents. PATIENTS OR OTHER PARTICIPANTS: Participants age 7-20 y with a body mass index that exceeded the 95th percentile for their age and sex. INTERVENTION(S): A standard oral glucose tolerance test. MAIN OUTCOME MEASURES: The adipose tissue insulin resistance index (calculated as the product of fasting insulin and FFA concentrations) (Adipose IR) and the area under curve of FFAs during the OGTT were compared between glucose tolerance categories. RESULTS: A total of 962 obese children and adolescents participated in this study. Adipose IR significantly increased across glucose tolerance categories (P for trend < .001). Within the normal glucose tolerance participants, an increase in adipose IR was observed related to an increase in 2-hr glucose levels. In a subsample of participants who underwent abdominal imaging for determination of lipid partitioning (n = 115), a tight relation of visceral fat (r = 0.34; P < .001) and the visceral/sc fat ratio (r = 0.55; P < .001) with the Adipose IR index was evident. Greater area under the curve FFAs (lower FFA suppression) during the OGTT was evident with worsening glucose tolerance (P for trend < .001). Glucose tolerance category, degree of obesity (body mass index-z score), IL-6, and low adiponectin emerged as significant predictors of the Adipose IR. CONCLUSIONS: Adipose IR is associated with reduced suppression of FFAs during the OGTT and with an altered adipocytokine profile. The negative relation with insulin secretion deserves further longitudinal investigation in the context of deteriorating glucose tolerance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Abdominal obesity and metabolic syndrome
Després, J.-P., & Lemieux, I. (2006) · Nature · doi:10.1038/nature05488 · Cited by 4,354 · cited 1×
“Although intra-abdominal fat has been shown not to contribute a greater proportion of systemic FFAs in relation to its share of total fat (30), it may be the source of other mediators having a mechanistic role in the development of systemic IR (16, 31).”
BackgroundSubcutaneous and visceral adipose tissue: their relation to the metabolic syndrome
Wajchenberg, B. L. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.6.0415 · Cited by 2,961 · cited 1×
“commonly detected in obese children (11).”
Cellular mechanisms of insulin resistance
Shulman, G. I. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10583 · Cited by 2,714
Pathophysiology of human visceral obesity: an update
Tchernof, A., & Després, J.-P. (2013) · Physiological Reviews · doi:10.1152/physrev.00033.2011 · Cited by 2,583 · cited 1×
“Specifically, macrophage infiltration into adipose depots has been shown to instigate whole-body low-grade inflammation, which in turn may have adverse effects in insulin-responsive tissues such as muscle and liver (32).”
BackgroundPrevalence of impaired glucose tolerance among children and adolescents with marked obesity
Sinha, R., Fisch, G., Teague, B., Tamborlane, W. V., Banyas, B., Allen, K., Savoye, M., Rieger, V., Taksali, S., Barbetta, G., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012578 · Cited by 1,709 · cited 1×
“Subjects were studied at the Yale Clinical Center Investigation at 0800 hours after a 10-hour overnight fast as previously reported (15).”
MethodSelf-citationMechanism of free fatty acid-induced insulin resistance in humans.
Roden, M., Price, T. B., Perseghin, G., Petersen, K. F., Rothman, D. L., Cline, G. W., & Shulman, G. I. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118742 · Cited by 1,539 · cited 2×
“in the development of reduced insulin sensitivity (7, 8) and -cell dysfunction (9, 10), both via lipotoxicity.”
BackgroundGroop, L. C., Bonadonna, R. C., DelPrato, S., Ratheiser, K., Zyck, K., Ferrannini, E., & DeFronzo, R. A. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114142 · Cited by 812 · cited 1×
“The Adipose Insulin Resistance index (Adipose IR) was calculated as the product of fasting insulin and FFA concentrations (22).”
MethodPhillips, D. I. W., Clark, P. M., Hales, C. N., & Osmond, C. (1994) · Diabetic Medicine · doi:10.1111/j.1464-5491.1994.tb00273.x · Cited by 631 · cited 1×
“The acute insulin response was derived from the insulinogenic index (18) as previously described (19).”
MethodYeckel, C. W., Weiss, R., Dziura, J., Taksali, S. E., Dufour, S., Burgert, T. S., Tamborlane, W. V., & Caprio, S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031503 · Cited by 352
Boden, G. (2003) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2003-39781 · Cited by 348 · cited 1×
“Specifically, elevated FFAs have been shown to acutely reduce whole-body insulin sensitivity during euglycemichypreinsulinemic clamps (7), to increase postabsorptive hepatic glucose production (25) and to reduce insulin secretion (26).”
BackgroundRoden, M., Stingl, H., Chandramouli, V, Schumann, W. C., Hofer, A., Landau, B. R., Nowotny, P., Waldhäusl, W., & Shulman, G. I. (2000) · Diabetes · doi:10.2337/diabetes.49.5.701 · Cited by 288 · cited 1×
“Specifically, elevated FFAs have been shown to acutely reduce whole-body insulin sensitivity during euglycemichypreinsulinemic clamps (7), to increase postabsorptive hepatic glucose production (25) and to reduce insulin secretion (26).”
BackgroundMetabolic Complications of Childhood Obesity
Weiss, R., & Kaufman, F. R. (2008) · Diabetes Care · doi:10.2337/dc08-s273 · Cited by 209
Dubé, J. J., Coen, P. M., DiStefano, G., Chacon, A. C., Helbling, N. L., Desimone, M. E., Stafanovic-Racic, M., Hames, K. C., Despines, A. A., Toledo, F. G. S., et al. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00257.2014 · Cited by 83 · cited 1×
“Greater systemic FFAs in the context of the postabsorptive state, as observed with worsening glucose tolerance in this study, may alter fuel utilization patterns in the muscle and liver in a manner promoting hyperglycemia by inducing alterations in the insulin signal transduction pathway leading to muscle and liver IR…”
BackgroundRegional Fat Deposition as a Factor in FFA Metabolism
Votruba, S. B., & Jensen, M. D. (2007) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.27.061406.093754 · Cited by 72
Cited by
Adipose Insulin Resistance in Normal-Weight Women With Polycystic Ovary Syndrome
Dumesic, D. A., Phan, J. D., Leung, K. L., Grogan, T. R., Ding, X., Li, X., Hoyos, L. R., Abbott, D. H., & Chazenbalk, G. D. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02086 · Cited by 92
Polycystic ovary syndrome as a plausible evolutionary outcome of metabolic adaptation
Dumesic, D. A., Padmanabhan, V., Chazenbalk, G. D., & Abbott, D. H. (2022) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-021-00878-y · Cited by 63
“These variables that adversely affect endocrine-metabolic function in PCOS were avoided in our studies by investigating healthy, normal-weight PCOS women by NIH criteria who were recruited from the general population to study a mild PCOS phenotype [17, 20] and who also were age- and BMI-balanced to controls to elimina…”
MethodSemnani-Azad, Z., Connelly, P. W., Bazinet, R. P., Retnakaran, R., Jenkins, D. J. A., Harris, S. B., Zinman, B., & Hanley, A. J. (2021) · Diabetes Care · doi:10.2337/dc20-1918 · Cited by 41
Aristizabal, J., González-Zapata, L., Estrada-Restrepo, A., Monsalve-Alvarez, J., Restrepo-Mesa, S., & Gaitán, D. (2018) · Nutrients · doi:10.3390/nu10010031 · Cited by 24
Metadata
- Authors
- Hershkop, K., Besor, O., Santoro, N., Pierpont, B., Caprio, S., & Weiss, R.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2016-06
- Volume
- 101
- Issue
- 6
- Pages
- 2423-2431
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2324513152
- Cited by
- 72
- References
- 14
- FWCI
- 7.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.